NASDAQ:ACAD - ACADIA Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$16.84 -0.24 (-1.41 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$16.84
Today's Range$16.61 - $17.41
52-Week Range$14.51 - $41.20
Volume3.01 million shs
Average Volume3.80 million shs
Market Capitalization$2.13 billion
P/E Ratio-7.14
Dividend YieldN/A
ACADIA Pharmaceuticals logoACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Receive ACAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio7.38
Quick Ratio7.26


Trailing P/E Ratio-7.14
Forward P/E Ratio-9.85
P/E GrowthN/A

Sales & Book Value

Annual Sales$124.90 million
Price / Sales16.83
Cash FlowN/A
Price / CashN/A
Book Value$2.70 per share
Price / Book6.24


EPS (Most Recent Fiscal Year)($2.36)
Net Income$-289,400,000.00
Net Margins-161.44%
Return on Equity-71.47%
Return on Assets-63.74%


Outstanding Shares124,830,000
Market Cap$2,132.03

ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its quarterly earnings results on Friday, May, 4th. The biopharmaceutical company reported ($0.44) EPS for the quarter, topping the Zacks' consensus estimate of ($0.56) by $0.12. The biopharmaceutical company had revenue of $48.90 million for the quarter, compared to analyst estimates of $47.06 million. ACADIA Pharmaceuticals had a negative return on equity of 71.47% and a negative net margin of 161.44%. ACADIA Pharmaceuticals's quarterly revenue was up 219.6% compared to the same quarter last year. During the same period last year, the company posted ($0.72) earnings per share. View ACADIA Pharmaceuticals' Earnings History.

When is ACADIA Pharmaceuticals' next earnings date?

ACADIA Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for ACADIA Pharmaceuticals.

What price target have analysts set for ACAD?

11 equities research analysts have issued 12 month target prices for ACADIA Pharmaceuticals' stock. Their forecasts range from $45.00 to $61.00. On average, they expect ACADIA Pharmaceuticals' share price to reach $50.40 in the next twelve months. This suggests a possible upside of 199.3% from the stock's current price. View Analyst Ratings for ACADIA Pharmaceuticals.

What is the consensus analysts' recommendation for ACADIA Pharmaceuticals?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about ACADIA Pharmaceuticals stock?

Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. " (5/9/2018)
  • 2. HC Wainwright analysts commented, "HARMONY Study Initiation: Killing Multiple" Birds With One Stone? Reit Buy and $60 PT Initiation of the Ph3 HARMONY study is one step forward with our bull thesis. With the initiation of HARMONY study in dementia-related psychosis (DRP) and discontinuation of SEREN study in AD agitation, we applaud what we view as a smart move by Acadia of pursuing a broader indication for pimavanserin, and more importantly, doing so with a solid clinical plan moving forward. At first glance, the seemingly bold move into DRP from ADP may appear over-ambitious (killing multiple" birds with one stone). However, we note that a psychosis focus/approach may prove to be a smart play from both the commercial point of view and also from the mechanistic perspective. The blessing from the FDA with a Breakthrough Designation further elevates our sanguine outlook for the program. We highlight the significant upside coming with the DRP expansion as the target market is potentially bigger than ADP alone (if we assume ADP comprises 70% of the DRP)." (10/5/2017)

Are investors shorting ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals saw a increase in short interest in June. As of June 15th, there was short interest totalling 15,212,475 shares, an increase of 20.5% from the May 31st total of 12,621,503 shares. Based on an average trading volume of 2,513,979 shares, the days-to-cover ratio is presently 6.1 days. Approximately 12.3% of the company's shares are sold short. View ACADIA Pharmaceuticals' Current Options Chain.

Who are some of ACADIA Pharmaceuticals' key competitors?

Who are ACADIA Pharmaceuticals' key executives?

ACADIA Pharmaceuticals' management team includes the folowing people:
  • Mr. Stephen R. Davis, Pres, CEO & Director (Age 57)
  • Mr. Todd S. Young, Exec. VP & CFO (Age 46)
  • Mr. Glenn F. Baity, Exec. VP, Gen. Counsel & Sec. (Age 48)
  • Dr. Srdjan R. Stankovic, Exec. VP and Head of R&D (Age 61)
  • Mr. Michael J. Yang, Exec. VP & Chief Commercial Officer (Age 56)

Has ACADIA Pharmaceuticals been receiving favorable news coverage?

Media stories about ACAD stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ACADIA Pharmaceuticals earned a coverage optimism score of 0.10 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 45.03 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Fred Alger Management Inc. (0.73%), Creative Planning (0.07%), Fox Run Management L.L.C. (0.02%), Amalgamated Bank (0.01%), Neville Rodie & Shaw Inc. (0.01%) and Stonebridge Capital Management Inc. (0.01%). Company insiders that own ACADIA Pharmaceuticals stock include Bros Advisors Lp Baker, Daniel B Soland, Edmund Harrigan, Glenn Baity, Laura Brege and Terrence O Moore. View Institutional Ownership Trends for ACADIA Pharmaceuticals.

Which institutional investors are selling ACADIA Pharmaceuticals stock?

ACAD stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management Inc. and Amalgamated Bank. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Glenn Baity and Laura Brege. View Insider Buying and Selling for ACADIA Pharmaceuticals.

Which institutional investors are buying ACADIA Pharmaceuticals stock?

ACAD stock was purchased by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C., Neville Rodie & Shaw Inc., Stonebridge Capital Management Inc. and Creative Planning. Company insiders that have bought ACADIA Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Daniel B Soland and Edmund Harrigan. View Insider Buying and Selling for ACADIA Pharmaceuticals.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $16.84.

How big of a company is ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals has a market capitalization of $2.13 billion and generates $124.90 million in revenue each year. The biopharmaceutical company earns $-289,400,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis. ACADIA Pharmaceuticals employs 425 workers across the globe.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]

MarketBeat Community Rating for ACADIA Pharmaceuticals (NASDAQ ACAD)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  544 (Vote Outperform)
Underperform Votes:  248 (Vote Underperform)
Total Votes:  792
MarketBeat's community ratings are surveys of what our community members think about ACADIA Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.